|
Saturday, November 28. 2009
Link:
http://www.positivedetroit.net/2009/11/detroit-medical-center-completes-first.html
Dr. Schmitt of the Detroit Medical Center Completes First Live Tweet of
Birmingham Hip Resurfacing Surgery
Friday, November 27, 2009
On Monday, November 24, the
Detroit Medical Center (DMC) conducted a live surgery simultaneously on
multiple social media platforms. The procedure, called Birmingham Hip
Resurfacing (first of its kind on social media), was performed conducted at DMC
Huron Valley-Sinai Hospital in Commerce Twp., MI.
Dr. Philip Schmitt, D.O., performed the 40-minute surgery, accompanied by a bevy
of healthcare professionals from the DMC Huron Valley-Sinai Hospital staff. Dr.
Schmitt was the first to perform the Birmingham Hip Resurfacing procedure in
Michigan and is considered one nation's best practitioners, having completed
nearly 600 operations to date. This particular procedure is ideal for patients
between the ages of 40 and 60 years old who are active, but suffer from constant
pains from arthritis or joint pain in the hips.
"Birmingham Hip Resurfacing is an exciting re-invention of technology, said
Philip Schmitt, D.O., of DMC Huron Valley-Sinai Hospital. "Americans love new
technology and at Huron Valley we embrace it for treating our patients. Adding
Twitter as another teaching aid benefits everyone."
Friday, November 13. 2009
DePuy Ortho to shutter British plant, lay off 280 workers
November 12, 2009
The orthopedics giant plans to stop making some of its older hip replacement
products at its factory in Leeds, England, as sales slide in favor of its newer
offerings.
DePuy Orthopaedics plans to shutter its manufacturing operations at a facility
in Leeds, England, after sales declines for some of its older hip replacement
products.
The Warsaw, Indiana-based orthpedics giant, which is a division of Johnson &
Johnson (JNJ) and has operations in Raynham, Mass., said it will phase out
manufacturing at the plant, laying off 280 workers, over the course of the rest
of this year and 2010.
The company is discontinuing an older line of hip replacement and resurfacing
products made in Leeds and relocating the production of other products to a
plant in Cork, Ireland.
Monday, November 9. 2009
ARLINGTON, Tenn.-(BUSINESS WIRE) - Nov. 9, 2009 - Wright
Medical Group, Inc. (NASDAQ: WMGI), a global orthopaedic
medical device company, announced today that the United
States Food and Drug Administration (FDA) has given approval
to the Company to market its original CONSERVE® Plus Total
Hip Resurfacing System. Now available in the United States,
this innovative total surface arthroplasty system provides
surgeons and their patients a bone-conserving alternative to
traditional total hip replacement.
The approval permits Wright to market CONSERVE® Plus in the
original femoral and acetabular component configuration
specified in its PreMarket Approval (PMA) application and
enables the Company to initiate efforts to introduce
additional enhancements to the system which are currently
only available outside of the United States. The Company
intends to incorporate these innovative future product
options into the CONSERVE® Plus System's femoral and acetabular component offerings via the PMA Supplement
pathway.
Hip resurfacing may be ideal for young, active patients in
need of surgical treatment for chronic pain. The CONSERVE®
Plus system is designed to offer pain relief and restoration
of function while retaining as much healthy bone as possible
and preserving future surgery options, including a primary
total hip replacement.
The approval follows a successful clinical trial involving
more than 1,300 patients, including those enrolled under
Continued Access protocols, providing patient data of
CONSERVE® Plus clinical data in postoperative periods of up
to eight years in length. Wright will commence surgeon
training in the first phase of its U.S. introduction. The
training is expected to begin immediately upon approval.
"Hip resurfacing represents a valuable alternative to
younger, more active patients who desire a hip
reconstruction that more anatomically mimics the natural
hip," commented Patrick Fisher, Sr. Director of Marketing
for Wright's hip franchise. "We have learned that this is an
excellent option for patients who meet the criteria for hip
resurfacing, and these individuals tend to be very
enthusiastic and outspoken about their positive results."
About Wright
Wright Medical Group, Inc. is a global orthopaedic medical
device company specializing in the design, manufacture and
marketing of reconstructive joint devices and biologics. The
Company has been in business for more than 50 years and
markets its products in over 60 countries worldwide. For
more information about Wright Medical, visit our website at
www.wmt.com
|
